Current and emerging medications for borderline personality disorder: is pharmacotherapy alone enough?

References

• American Psychiatric Association. Diagnostic and statistical manual for mental disorders. 5th ed. (DSM-5). Arlington, VA: American Psychiatric Publishing. 2013.
   Google Scholar
• Frankenburg FR, Zanarini MC. The association between borderline personality disorder and chronic medical illnesses, poor health-related lifestyle choices, and costly forms of health care utilization. J Clin Psychiatry. 2004 Dec;65(12):1660–1665.
   PubMed Web of Science ®Google Scholar
• Ansell EB, Sanislow CA, McGlashan TH, et al. Psychosocial impairment and treatment utilization by patients with borderline personality disorder, other personality disorders, mood and anxiety disorders, and a healthy comparison group. Compr Psychiatry. 2007 Jul - Aug;48(4):329–336. Epub 2007 Apr 6.
   PubMed Web of Science ®Google Scholar
• Skodol AE, Pagano ME, Bender DS, et al. Stability of functional impairment in patients with schizotypal, borderline, avoidant, or obsessive-compulsive personality disorder over two years. Psychol Med. 2005 Mar;35(3):443–451.
   PubMed Web of Science ®Google Scholar
• Tomko RL, Trull TJ, Wood PK, et al. Characteristics of borderline personality disorder in a community sample: comorbidity, treatment utilization, and general functioning. J Pers Disord. 2014 Oct;28(5):734–750.
   PubMed Web of Science ®Google Scholar
• Miller AL, Muehlenkamp JJ, Jacobson CM. Fact or fiction: diagnosing borderline personality disorder in adolescents. Clin Psychol Rev. 2008 Jul;28(6):969–981. Epub 2008 Mar 10.
   PubMed Web of Science ®Google Scholar
• Kaess M, Brunner R, Chanen A. Borderline personality disorder in adolescence. Pediatrics. 2014 Oct;134(4):782–793. Epub 2014 Sep 22.
   PubMed Web of Science ®Google Scholar
• Bozzatello P, Bellino S, Bosia M, et al. Early detection and outcome in borderline personality disorder. Front Psychiatry. 2019;10:710. doi: 10.3389/fpsyt.2019.00710. eCollection 2019.
   Web of Science ®Google Scholar
• Leichsenring F, Leibing E, Kruse J, et al. Borderline personality disorder. Lancet. 2011 Jan 1;377(9759):74–84.
   PubMed Web of Science ®Google Scholar
• Gunderson JG. Borderline personality disorder: ontogeny of a diagnosis. Am J Psychiatry. 2009 May;166(5):530–539.
   PubMed Web of Science ®Google Scholar
• Lenzenweger MF, Pastore RE. On determining sensitivity to pain in borderline personality disorder. Arch Gen Psychiatry. 2007 Jun;64(6):747–748. author reply 748-9.
   PubMed Web of Science ®Google Scholar
• Gunderson JG, Links PS. Borderline personality disorder: a clinical guide. Arlington, VA: Amer Psychiatric Pub Inc; 2008.
   Google Scholar
• Tomko RL, Brown WC, Tragesser SL, et al. Social context of anger in borderline personality disorder and depressive disorders: findings from a naturalistic observation study. J Pers Disord. 2014 Jun;28(3):434–448. Epub 2012 Sep 17.
   PubMed Web of Science ®Google Scholar
• Grant BF, Goldstein RB, Chou SP, et al. Sociodemographic and psychopathologic predictors of first incidence of DSM-IV substance use, mood and anxiety disorders: results from the wave 2 national epidemiologic survey on alcohol and related conditions. Mol Psychiatry. 2009 Nov;14(11):1051–1066. Epub 2008 Apr 22.
   PubMed Web of Science ®Google Scholar
• Zanarini MC, Frankenburg FR, Hennen J, et al. Mental health service utilization by borderline personality disorder patients and axis II comparison subjects followed prospectively for 6 years. J Clin Psychiatry. 2004 Jan;65(1):28–36.
   PubMed Web of Science ®Google Scholar
• Cristea IA, Gentili C, Cotet CD, et al. Efficacy of psychotherapies for borderline personality disorder: a systematic review and meta-analysis. JAMA Psychiatry. 2017 Apr 1;74(4):319–328.
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Practice guideline for the treatment of patients with borderline personality disorder. Am J Psychiatry. 2001;158:1–52.
   Web of Science ®Google Scholar
• Oldham JM, Bender DS, Skodol AE, et al. Testing an APA practice guideline: symptom-targeted medication utilization for patients with borderline personality disorder. J Psychiatr Pract. 2004 May;10(3):156–161.
   PubMedGoogle Scholar
• Herpertz SC, Zanarini M, Schulz CS, et al. WFSBP task force on personality disorders; world federation of societies of biological psychiatry (wfsbp). world federation of societies of biological psychiatry (wfsbp) guidelines for biological treatment of personality disorders. World J Biol Psychiatry. 2007;8(4):212–244.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence (NICE) Borderline Personality Disorder: treatment and management. Clinical Guideline 78. London, UK: National Collaborating Centre for Mental Health; 2009. Available from: www.nice.org.uk/guidance/cg78
   Google Scholar
• National Institute for Health and Clinical Excellence (NICE) Personality Disorders: borderline and antisocial. London, UK: National Collaborating Centre for Mental Health; 2015. Available from: www.nice.org.uk/guidance/qs88
   Google Scholar
• Bozzatello P, Ghirardini C, Uscinska M, et al. Pharmacotherapy of personality disorders: what we know and what we have to search for. Future Neurol. 2017;12(4):199–222.
   Web of Science ®Google Scholar
• National Health and Medical Research Council. Australian Government. Clinical Practice guidelines for the management of borderline personalità disorder. Melbourne: National Health and Medical Research Council; 2012.
   Google Scholar
• Stoffers JM, Völlm BA, Rücker G, et al. Pharmacological interventions for borderline personality disorder. Cochrane Database Syst Rev. 2010;16(6):CD005653.
   Google Scholar
• Stoffers JM, Lieb K. Pharmacotherapy for borderline personality disorder–current evidence and recent trends. Curr Psychiatry Rep. 2015 Jan; 17(1):534.
   PubMed Web of Science ®Google Scholar
• Coccaro EF, Berman ME, Kavoussi RJ. Assessment of life history of aggression: development and psychometric characteristics. Psychiatry Res. 1997 Dec 5;73(3):147–157.
   PubMed Web of Science ®Google Scholar
• Hancock-Johnson E, Griffiths C, Picchioni M. A focused systematic review of pharmacological treatment for borderline personality disorder. CNS Drugs. 2017 May;31(5):345–356.
   PubMed Web of Science ®Google Scholar
• Salzman C, Wolfson AN, Schatzberg A, et al. Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder. J Clin Psychopharmacol. 1995 Feb;15(1):23–29.
   PubMed Web of Science ®Google Scholar
• Markovitz P. Pharmacotherapy of impulsivity, aggression, and related disorders. In: Hollander E, Stein DJ, editors. Impulsivity and aggression. NY, USA: John Wiley & Sons; 1995. p. 263–287.
   Google Scholar
• Coccaro EF, Kavoussi RJ. Fluoxetine and impulsive aggressive behavior in personality-disordered subjects. Arch Gen Psychiatry. 1997 Dec;54(12):1081–1088.
   PubMed Web of Science ®Google Scholar
• Simpson EB, Yen S, Costello E, et al. Combined dialectical behavior therapy and fluoxetine in the treatment of borderline personality disorder. J Clin Psychiatry. 2004 Mar;65(3):379–385.
   PubMed Web of Science ®Google Scholar
• Zanarini MC, Frankenburg FR, Parachini EA. A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder. J Clin Psychiatry. 2004 Jul;65(7):903–907.
   PubMed Web of Science ®Google Scholar
• Bellino S, Rinaldi C, Bogetto F. Adaptation of interpersonal psychotherapy to borderline personality disorder: a comparison of combined therapy and single pharmacotherapy. Can J Psychiatry. 2010 Feb;55(2):74–81.
   PubMed Web of Science ®Google Scholar
• Rinne T, van den Brink W, Wouters L, et al. SSRI treatment of borderline personality disorder: a randomized, placebo-controlled clinical trial for female patients with borderline personality disorder. Am J Psychiatry. 2002 Dec;159(12):2048–2054.
   PubMed Web of Science ®Google Scholar
• Jariani M, Saaki M, Nazari H, et al. the effect of olanzapine and sertraline on personality disorder in patients with methadone maintenance therapy. Psychiatr Danub. 2010 Dec;22(4):544–547.
   PubMed Web of Science ®Google Scholar
• Markovitz PJ, Wagner SC. Venlafaxine in the treatment of borderline personality disorder. Psychopharmacol Bull. 1995;31(4):773–777.
   PubMedGoogle Scholar
• Bellino S, Paradiso E, Bozzatello P, et al. Efficacy and tolerability of duloxetine in the treatment of patients with borderline personality disorder: a pilot study. J Psychopharmacol. 2010 Mar;24(3):333–339. Epub 2008 Aug 21.
   PubMed Web of Science ®Google Scholar
• Mercer D, Douglass AB, Links PS. Meta-analyses of mood stabilizers, antidepressants and antipsychotics in the treatment of borderline personality disorder: effectiveness for depression and anger symptoms. J Pers Disord. 2009 Apr;23(2):156–174.
   PubMed Web of Science ®Google Scholar
• Links P, Steiner M, Boiago I, et al. Lithium therapy for borderline patients: preliminary findings. J Personal Disord. 1990;4:173–181.
   Google Scholar
• de la Fuente JM, Lotstra F. A trial of carbamazepine in borderline personality disorder. Eur Neuropsychopharmacol. 1994 Dec;4(4):479–486.
   PubMed Web of Science ®Google Scholar
• Hollander E, Allen A, Lopez RP, et al. A preliminary double-blind, placebo-controlled trial of divalproex sodium in borderline personality disorder. J Clin Psychiatry. 2001 Mar;62(3):199–203.
   PubMed Web of Science ®Google Scholar
• Hollander E 1, Swann AC, Coccaro EF, et al. Impact of trait impulsivity and state aggression on divalproex versus placebo response in borderline personality disorder. Am J Psychiatry. 2005 Mar;162(3):621–624.
   PubMed Web of Science ®Google Scholar
• Frankenburg FR, Zanarini MC. Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder: a double-blind placebo-controlled pilot study. J Clin Psychiatry. 2002 May;63(5):442–446.
   PubMed Web of Science ®Google Scholar
• Moen R, Freitag M, Miller M, et al. Efficacy of extended-release divalproex combined with “condensed” dialectical behavior therapy for individuals with borderline personality disorder. Ann Clin Psychiatry. 2012 Nov;24(4):255–260.
   PubMed Web of Science ®Google Scholar
• Bellino S, Bozzatello P, Rocca G, et al. Efficacy of omega-3 fatty acids in the treatment of borderline personality disorder: a study of the association with valproic acid. J Psychopharmacol. 2014 Feb;28(2):125–132. Epub 2013 Nov 5.
   PubMed Web of Science ®Google Scholar
• Nickel MK, Nickel C, Mitterlehner FO, et al. Topiramate treatment of aggression in female borderline personality disorder patients: a double-blind, placebo-controlled study. J Clin Psychiatry. 2004 Nov;65(11):1515–1519.
   PubMed Web of Science ®Google Scholar
• Nickel MK, Nickel C, Kaplan P, et al. Treatment of aggression with topiramate in male borderline patients: a double-blind, placebo-controlled study. Biol Psychiatry. 2005 Mar 1;57(5):495–499.
   PubMed Web of Science ®Google Scholar
• Nickel MK. Topiramate treatment of aggression in male borderline patients. Aust N Z J Psychiatry. 2007 May;41(5):461–462.
   PubMed Web of Science ®Google Scholar
• Nickel M. Topiramate reduced aggression in female patients with borderline personality disorder. Eur Arch Psychiatry Clin Neurosci. 2007 Oct;257(7):432–433.
   PubMed Web of Science ®Google Scholar
• Nickel MK, Loew TH. Treatment of aggression with topiramate in male borderline patients, part II: 18-month follow-up. Eur Psychiatry. 2008 Mar;23(2):115–117. Epub 2007 Nov 19.
   PubMed Web of Science ®Google Scholar
• Loew TH, Nickel MK. Topiramate treatment of women with borderline personality disorder, part II: an open 18-month follow-up. J Clin Psychopharmacol. 2008 Jun;28(3):355–357.
   PubMed Web of Science ®Google Scholar
• Tritt K, Nickel C, Lahmann C, et al. Lamotrigine treatment of aggression in female borderline-patients: a randomized, double-blind, placebo-controlled study. J Psychopharmacol. 2005 May;19(3):287–291.
   PubMed Web of Science ®Google Scholar
• Reich DB, Zanarini MC, Bieri KA. A preliminary study of lamotrigine in the treatment of affective instability in borderline personality disorder. Int Clin Psychopharmacol. 2009 Sep;24(5):270–275.
   PubMed Web of Science ®Google Scholar
• Leiberich P, Nickel MK, Tritt K, et al. Lamotrigine treatment of aggression in female borderline patients, part II: AN 18-month follow-up. J Psychopharmacol. 2008 Sep;22(7):805–808. Epub 2008 Feb 28.
   PubMed Web of Science ®Google Scholar
• Crawford MJ, Sanatinia R, Barrett B, et al. the clinical effectiveness and cost-effectiveness of lamotrigine in borderline personality disorder: a randomized placebo-controlled trial. Am J Psychiatry. 2018 Aug 1;175(8):756–764.
   PubMed Web of Science ®Google Scholar
• Bellino S, Paradiso E, Bogetto F. Oxcarbazepine in the treatment of borderline personality disorder: a pilot study. J Clin Psychiatry. 2005 Sep;66(9):1111–1115.
   PubMed Web of Science ®Google Scholar
• Montgomery SA. The psychopharmacology of borderline personality disorders. Acta Psychiatr Belg. 1987 May - Jun;87(3):260–266.
   PubMedGoogle Scholar
• Leone NF. Response of borderline patients to loxapine and chlorpromazine. J Clin Psychiatry. 1982 Apr;43(4):148–150.
   PubMed Web of Science ®Google Scholar
• Goldberg SC, Schulz SC, Schulz PM, et al. Borderline and schizotypal personality disorders treated with low-dose thiothixene vs placebo. Arch Gen Psychiatry. 1986 Jul;43(7):680–686.
   PubMed Web of Science ®Google Scholar
• Cowdry RW, Gardner DL. Pharmacotherapy of borderline personality disorder. alprazolam, carbamazepine, trifluoperazine, and tranylcypromine. Arch Gen Psychiatry. 1988 Feb;45(2):111–119.
   PubMed Web of Science ®Google Scholar
• Cornelius JR, Soloff PH, Perel JM, et al. Continuation pharmacotherapy of borderline personality disorder with haloperidol and phenelzine. Am J Psychiatry. 1993 Dec;150(12):1843–1848.
   PubMed Web of Science ®Google Scholar
• Soloff PH, Cornelius J, George A, et al. Efficacy of phenelzine and haloperidol in borderline personality disorder. Arch Gen Psychiatry. 1993 May;50(5):377–385.
   PubMed Web of Science ®Google Scholar
• Bellino S, Bozzatello P, Brignolo E, et al. New antipsychotics in treatment of mood instability and cognitive perceptual symptoms in borderline personality disorder. Current Psychopharmacology. 2012;1(Issue):1.
   Google Scholar
• Ripoll LH. Clinical psychopharmacology of borderline personality disorder: an update on the available evidence in light of the diagnostic and statistical manual of mental disorders - 5. Curr Opin Psychiatry. 2012 Jan;25(1):52–58.
   PubMed Web of Science ®Google Scholar
• Stahl SM. Stahl’s essential psychopharmacology: neuroscientific basis and practical applications. New York, NY: Cambridge Medicine; 2013. ( Paperback)
   Google Scholar
• Frankenburg FR, Zanarini MC. Clozapine treatment of borderline patients: a preliminary study. Compr Psychiatry. 1993 Nov - Dec;34(6):402–405.
   PubMed Web of Science ®Google Scholar
• Benedetti F, Sforzini L, Colombo C, et al. Low-dose clozapine in acute and continuation treatment of severe borderline personality disorder. J Clin Psychiatry. 1998 Mar;59(3):103–107.
   PubMed Web of Science ®Google Scholar
• Chengappa KN, Ebeling T, Kang JS, et al. Clozapine reduces severe self-mutilation and aggression in psychotic patients with borderline personality disorder. J Clin Psychiatry. 1999 Jul;60(7):477–484.
   PubMed Web of Science ®Google Scholar
• Parker GF. Clozapine and borderline personality disorder. Psychiatr Serv. 2002 Mar;53(3):348–349.
   PubMed Web of Science ®Google Scholar
• Rohde C, Polcwiartek C, Correll CU, et al. Real-world effectiveness of clozapine for borderline personality disorder: results from a 2-year mirror-image study. J Pers Disord. 2018 Dec;32(6):823–837. Epub 2017 Nov 9.
   PubMed Web of Science ®Google Scholar
• Rocca P, Marchiaro L, Cocuzza E, et al. Treatment of borderline personality disorder with risperidone. J Clin Psychiatry. 2002 Mar;63(3):241–244.
   PubMed Web of Science ®Google Scholar
• Friedel RO, Jackson WT, Huston CS, et al. Risperidone treatment of borderline personality disorder assessed by a borderline personality disorder-specific outcome measure: a pilot study. J Clin Psychopharmacol. 2008 Jun;28(3):345–347.
   PubMed Web of Science ®Google Scholar
• Díaz-Marsá M, Galian M, Montes A, et al. Long-acting injectable risperidone in treatment resistant borderline personality disorder. A small series report. Actas Esp Psiquiatr. 2008 Mar - Apr;36(2):70–74.
   PubMed Web of Science ®Google Scholar
• Carrasco JL, Palomares N, Marsá MD. Effectiveness and tolerability of long-acting intramuscular risperidone as adjuvant treatment in refractory borderline personality disorder. Psychopharmacology (Berl). 2012 Nov;224(2):347–348. Epub 2012 Oct 11.
   PubMed Web of Science ®Google Scholar
• Szigethy EM, Schulz SC. Risperidone in comorbid borderline personality disorder and dysthymia. J Clin Psychopharmacol. 1997 Aug;17(4):326–327.
   PubMed Web of Science ®Google Scholar
• Bellino S, Bozzatello P, Rinaldi C, et al. Paliperidone ER in the treatment of borderline personality disorder: a pilot study of efficacy and tolerability. Depress Res Treat. 2011;2011:680194. Epub 2011 Aug 4.
   PubMedGoogle Scholar
• Palomares N, Montes A, Díaz-Marsá M, et al. Effectiveness of long-acting paliperidone palmitate in borderline personality disorder. Int Clin Psychopharmacol. 2015 Nov;30(6):338–341.
   PubMed Web of Science ®Google Scholar
• Zanarini MC, Frankenburg FR. Olanzapine treatment of female borderline personality disorder patients: a double-blind, placebo-controlled pilot study. J Clin Psychiatry. 2001 Nov;62(11):849–854.
   PubMed Web of Science ®Google Scholar
• Bogenschutz MP, Nurnberg GH. Olanzapine versus placebo in the treatment of borderline personality disorder. J Clin Psychiatry. 2004 Jan;65(1):104–109.
   PubMed Web of Science ®Google Scholar
• Schulz SC, Zanarini MC, Bateman A, et al. Olanzapine for the treatment of borderline personality disorder: variable dose 12-week randomised double-blind placebo-controlled study. Br J Psychiatry. 2008 Dec;193(6):485–492.
   PubMed Web of Science ®Google Scholar
• Zanarini MC, Schulz SC, Detke HC, et al. A dose comparison of olanzapine for the treatment of borderline personality disorder: a 12-week randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2011 Oct;72(10):1353–1362.
   PubMed Web of Science ®Google Scholar
• Soler J, Pascual JC, Campins J, et al. Double-blind, placebo-controlled study of dialectical behavior therapy plus olanzapine for borderline personality disorder. Am J Psychiatry. 2005 Jun;162(6):1221–1224.
   PubMed Web of Science ®Google Scholar
• Linehan MM, McDavid JD, Brown MZ, et al. Olanzapine plus dialectical behavior therapy for women with high irritability who meet criteria for borderline personality disorder: a double-blind, placebo-controlled pilot study. J Clin Psychiatry. 2008 Jun;69(6):999–1005.
   PubMed Web of Science ®Google Scholar
• Jariani M, Saaki M, Nazari H, et al. The effect of olanzapine and sertraline on personality disorder in patients with methadone maintenance therapy. Psychiatr Danub. 2010 Dec;22(4):544–547.
   PubMed Web of Science ®Google Scholar
• Shafti SS, Shahveisi B. Olanzapine versus haloperidol in the management of borderline personality disorder: a randomized double-blind trial. J Clin Psychopharmacol. 2010 Feb;30(1):44–47..
   PubMed Web of Science ®Google Scholar
• Bozzatello P, Rocca P, Uscinska M, et al. Efficacy and tolerability of asenapine compared with olanzapine in borderline personality disorder: an open-label randomized controlled trial. CNS Drugs. 2017 Sep;31(9):809–819.
   PubMed Web of Science ®Google Scholar
• Shafti SS, Kaviani H. A comparative study between olanzapine and aripiprazole for management of female borderline personality symptoms. Bull Clin Psychopharmacol. 2015 March;25(1):1.
   Google Scholar
• Nickel MK, Muehlbacher M, Nickel C, et al. Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebo-controlled study. Am J Psychiatry. 2006 May;163(5):833–838.
   PubMed Web of Science ®Google Scholar
• Nickel MK, Loew TH, Pedrosa GF. Aripiprazole in treatment of borderline patients, part II: an 18-month follow-up. Psychopharmacology (Berl). 2007 May;191(4):1023–1026. Epub 2007 Feb 23.
   PubMed Web of Science ®Google Scholar
• Bellino S, Bozzatello P, Brignolo E, et al. Antipsychotics in the treatment of impulsivity in personality disorders and impulse control disorders. Current Psychopharmacology. 2013;2: 5–17. 2211-5579/13 $58.00+.00.
   Google Scholar
• Bellino S, Paradiso E, Bogetto F. Efficacy and tolerability of aripiprazole augmentation in sertraline-resistant patients with borderline personality disorder. Psychiatry Res. 2008;161(2):206–212.
   PubMed Web of Science ®Google Scholar
• Chanen AM, Betts J, Jackson H, et al. Aripiprazole compared with placebo for auditory verbal hallucinations in youth with borderline personality disorder: protocol for the VERBATIM randomized controlled trial. Early Interv Psychiatry. 2019 Jan 28. DOI:10.1111/eip.12774.
   Web of Science ®Google Scholar
• Adityanjee SSC. Clinical use of quetiapine in disease states other than schizophrenia. J Clin Psychiatry. 2002;63(Suppl 13):32–38.
   PubMedGoogle Scholar
• Adityanjee A, Romine A, Brown E, et al. Quetiapine in patients with borderline personality disorder: an open-label trial. Ann Clin Psychiatry. 2008 Oct - Dec;20(4):219–226.
   PubMed Web of Science ®Google Scholar
• Villeneuve E, Lemeline S. Open-label study of atypical neuroleptic quetiapine for treatment of borderline personality disorder: impulsivity as main target. J Clin Psychiatry. 2005 Oct;66(10):1298–1303.
   PubMed Web of Science ®Google Scholar
• Bellino S, Paradiso E, Bogetto F. Efficacy and tolerability of quetiapine in the treatment of borderline personality disorder: A pilot study. J Clin Psychiatry. 2006 Jul;67(7):1042–1046.
   PubMed Web of Science ®Google Scholar
• Perrella C, Carrus D, Costa E, et al. Quetiapine for the treatment of borderline personality disorder; an open-label study. Prog Neuropsychopharmacol Biol Psychiatry. 2007 Jan 30;31(1):158–163. Epub 2006 Oct 11.
   PubMed Web of Science ®Google Scholar
• Roepke S, Merkl A, Dams A, et al. Preliminary evidence of improvement of depressive symptoms but not impulsivity in cluster B personality disorder patients treated with quetiapine: an open label trial. Pharmacopsychiatry. 2008 Sep;41(5):176–181. Epub 2008 Sep 1.
   PubMed Web of Science ®Google Scholar
• Van den Eynde F, Senturk V, Naudts K, et al. Efficacy of quetiapine for impulsivity and affective symptoms in borderline personality disorder. J Clin Psychopharmacol. 2008 Apr;28(2):147–155.
   PubMed Web of Science ®Google Scholar
• Black DW, Zanarini MC, Romine A, et al. Comparison of low and moderate dosages of extended-release quetiapine in borderline personality disorder: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry. 2014 Nov 1;171(11):1174–1182.
   PubMed Web of Science ®Google Scholar
• Lee SS, Allen J, Black DW, et al. Quetiapine’s effect on the SCL-90-R domains in patients with borderline personality disorder. Ann Clin Psychiatry. 2016 Feb;28(1):4–10.
   PubMed Web of Science ®Google Scholar
• Martín-Blanco A, Patrizi B, Villalta L, et al. Asenapine in the treatment of borderline personality disorder: an atypical antipsychotic alternative. Int Clin Psychopharmacol. 2014 Mar;29(2):120–123.
   PubMed Web of Science ®Google Scholar
• Pascual JC, Oller S, Soler J, et al. Ziprasidone in the acute treatment of borderline personality disorder in psychiatric emergency services. J Clin Psychiatry. 2004 Sep;65(9):1281–1282.
   PubMed Web of Science ®Google Scholar
• Pascual JC 1, Soler J, Puigdemont D, et al. Ziprasidone in the treatment of borderline personality disorder: a double-blind, placebo-controlled, randomized study. J Clin Psychiatry. 2008 Apr;69(4):603–608.
   PubMed Web of Science ®Google Scholar
• Kahl KG, Negt P, Wollmer A, et al. Inhaled loxapine for acute treatment of agitation in patients with borderline personality disorder: a case series. J Clin Psychopharmacol. 2015 Dec;35(6):741–743.
   PubMed Web of Science ®Google Scholar
• Krüger TH, Wollmer MA, Negt P, et al. Inhaled loxapine for emergency treatment of agitated patients with borderline personality disorder: A series of five cases. Nervenarzt. 2016 Nov;87(11):1222–1226.
   PubMed Web of Science ®Google Scholar
• Patrizi B, Navarro-Haro MV, Gasol M. Inhaled loxapine for agitation in patients with personality disorder: an initial approach. Eur Neuropsychopharmacol. 2019 Jan;29(1):122–126. Epub 2018 Nov 26.
   PubMed Web of Science ®Google Scholar
• de Berardis D, Fornaro M, Orsolini L, et al. The role of inhaled loxapine in the treatment of acute agitation in patients with psychiatric disorders: a clinical review. Int J Mol Sci. 2017 Feb 8;18(2):pii: E349.
   Web of Science ®Google Scholar
• Bellino S, Rinaldi C, Bozzatello P, et al. Recent approaches to pharmacotherapy of personality disorders. Neuropsych. 2011;1(3):259–273.
   Google Scholar
• Philipsen A, Schmahl C, Lieb K. Naloxone in the treatment of acute dissociative states in female patients with borderline personality disorder. Pharmacopsychiatry. 2004 Sep;37(5):196–199.
   PubMed Web of Science ®Google Scholar
• Schmahl C, Kleindienst N, Limberger M, et al. Evaluation of naltrexone for dissociative symptoms in borderline personality disorder. Int Clin Psychopharmacol. 2012 Jan;27(1):61–68.
   PubMed Web of Science ®Google Scholar
• Martín-Blanco A, Patrizi B, Soler J, et al. Use of nalmefene in patients with comorbid borderline personality disorder and alcohol use disorder: a preliminary report. Int Clin Psychopharmacol. 2017 Jul;32(4):231–234.
   PubMed Web of Science ®Google Scholar
• Bartz J, Simeon D, Hamilton H, et al. Oxytocin can hinder trust and cooperation in borderline personality disorder. Soc Cogn Affect Neurosci. 2011 Oct;6(5):556–563. Epub 2010 Nov 29.
   PubMed Web of Science ®Google Scholar
• Simeon D, Bartz J, Hamilton H, et al. Oxytocin administration attenuates stress reactivity in borderline personality disorder: a pilot study. Psychoneuroendocrinology. 2011 Oct;36(9):1418–1421. Epub 2011 May 4.
   PubMed Web of Science ®Google Scholar
• Bertsch K, Gamer M, Schmidt B, et al. Oxytocin and reduction of social threat hypersensitivity in women with borderline personality disorder. Am J Psychiatry. 2013 Oct;170(10):1169–1177.
   PubMed Web of Science ®Google Scholar
• Brüne M, Ebert A, Kolb M, et al. Oxytocin influences avoidant reactions to social threat in adults with borderline personality disorder. Hum Psychopharmacol. 2013 Nov;28(6):552–561.
   PubMed Web of Science ®Google Scholar
• Brüne M, Kolb M, Ebert A, et al. Nonverbal communication of patients with borderline personality disorder during clinical interviews: a double-blind placebo-controlled study using intranasal oxytocin. J Nerv Ment Dis. 2015 Feb;203(2):107–111.
   PubMed Web of Science ®Google Scholar
• Ebert A, Kolb M, Heller J, et al. Modulation of interpersonal trust in borderline personality disorder by intranasal oxytocin and childhood trauma. Soc Neurosci. 2013;8(4):305–313.
   PubMed Web of Science ®Google Scholar
• Philipsen A, Richter H, Schmahl C, et al. Clonidine in acute aversive inner tension and self-injurious behavior in female patients with borderline personality disorder. J Clin Psychiatry. 2004 Oct;65(10):1414–1419.
   PubMed Web of Science ®Google Scholar
• Ziegenhorn AA, Roepke S, Schommer NC, et al. Clonidine improves hyperarousal in borderline personality disorder with or without comorbid posttraumatic stress disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2009 Apr;29(2):170–173.
   PubMed Web of Science ®Google Scholar
• Zanarini MC, Frankenburg FR. omega-3 fatty acid treatment of women with borderline personality disorder: a double-blind, placebo-controlled pilot study. Am J Psychiatry. 2003 Jan;160(1):167–169.
   PubMed Web of Science ®Google Scholar
• Hallahan B, Hibbeln JR, Davis JM, et al. Omega-3 fatty acid supplementation in patients with recurrent self-harm. single-centre double-blind randomised controlled trial. Br J Psychiatry. 2007 Feb;190:118–122.
   PubMed Web of Science ®Google Scholar
• Amminger GP, Chanen AM, Ohmann S, et al. Omega-3 fatty acid supplementation in adolescents with borderline personality disorder and ultra-high risk criteria for psychosis: a post hoc subgroup analysis of a double-blind, randomized controlled trial. Can J Psychiatry. 2013 Jul;58(7):402–408.
   PubMed Web of Science ®Google Scholar
• Bozzatello P, Rocca P, Bellino S. Combination of omega-3 fatty acids and valproic acid in treatment of borderline personality disorder: a follow-up study. Clin Drug Investig. 2018 Apr;38(4):367–372.
   PubMed Web of Science ®Google Scholar
• Grosjean B, Tsai GE. NMDA neurotransmission as a critical mediator of borderline personality disorder. J Psychiatry Neurosci. 2007 Mar;32(2):103–115.
   PubMed Web of Science ®Google Scholar
• Kulkarni J, Thomas N, Hudaib AR, et al. Effect of the glutamate NMDA receptor antagonist memantine as adjunctive treatment in borderline personality disorder: an exploratory, randomised, double-blind, placebo-controlled trial. CNS Drugs. 2018 Feb;32(2):179–187.
   PubMed Web of Science ®Google Scholar
• Rammes G, Danysz W, Parsons CG. Pharmacodynamics of memantine: an update. Curr Neuropharmacol. 2008 Mar;6(1):55–78.
   PubMed Web of Science ®Google Scholar
• Borschmann R, Henderson C, Hogg J, et al. Crisis interventions for people with borderline personality disorder. Cochrane Database Syst Rev. 2012 Jun 13; 6. doi: 10.1002/14651858.CD009353.pub2. CD009353.
   PubMed Web of Science ®Google Scholar
• Boyce P, Carter G, Penrose-Wall J. Summary australian and new zealand clinical practice guideline for the management of adult deliberate self-harm. Australas Psychiatry. 2003;11(2):150–155.
   Google Scholar
• Linehan MM. Dialectical behavior therapy for treatment of borderline personality disorder: implications for the treatment of substance abuse. NIDA Res Monogr. 1993;137:201–216.
   PubMedGoogle Scholar
• Bateman AW, Fonagy P. Mentalization-based treatment of BPD. J Pers Disord. 2004 Feb;18(1):36–51.
   PubMed Web of Science ®Google Scholar
• Angus L, Gillies LA. Counselling the borderline client: an interpersonal approach. Can J of Counselling.1994;28:69–83.
   Google Scholar
• Markowitz JC, Skodol AE, Bleiberg K. Interpersonal psychotherapy for borderline personality disorder: possible mechanisms of change. J Clin Psychol. 2006 Apr;62(4):431–444.
   PubMed Web of Science ®Google Scholar
• Bateman AW. Interpersonal psychotherapy for borderline personality disorder. Clin Psychol Psychother. 2012 Mar - Apr;19(2):124–133. Epub 2012 Feb 20.
   PubMed Web of Science ®Google Scholar
• Bellino S, Bozzatello P, De Grandi E, et al. Interpersonal psychotherapy: a model of intervention for borderline personality disorder. Riv Psichiatr. 2014 Jul - Aug;49(4):158–163.
   PubMed Web of Science ®Google Scholar
• Bellino S, Bozzatello P, Bogetto F. Combined treatment of borderline personality disorder with interpersonal psychotherapy and pharmacotherapy: predictors of response. Psychiatry Res. 2015 Mar 30;226(1):284–288. Epub 2015 Jan 13.
   PubMed Web of Science ®Google Scholar
• Bozzatello P, Bellino S. Combined therapy with interpersonal psychotherapy adapted for borderline personality disorder: A two-years follow-up. Psychiatry Res. 2016 Jun 30;240:151–156. Epub 2016 Apr 13.
   PubMed Web of Science ®Google Scholar
• Nosè M, Cipriani A, Biancosino B, et al. Efficacy of pharmacotherapy against core traits of borderline personality disorder: meta-analysis of randomized controlled trials. Int Clin Psychopharmacol. 2006 Nov;21(6):345–353.
   PubMed Web of Science ®Google Scholar
• Ingenhoven T, Lafay P, Rinne T, et al. Effectiveness of pharmacotherapy for severe personality disorders: meta-analyses of randomized controlled trials. J Clin Psychiatry. 2010 Jan;71(1):14–25.
   PubMed Web of Science ®Google Scholar
• Ingenhoven TJ, Duivenvoorden HJ. Differential effectiveness of antipsychotics in borderline personality disorder: meta-analyses of placebo-controlled, randomized clinical trials on symptomatic outcome domains. J Clin Psychopharmacol. 2011 Aug;31(4):489–496.
   PubMed Web of Science ®Google Scholar
• Vita A, De Peri L, Sacchetti E. Antipsychotics, antidepressants, anticonvulsants, and placebo on the symptom dimensions of borderline personality disorder: a meta-analysis of randomized controlled and open-label trials. J Clin Psychopharmacol. 2011 Oct;31(5):613–624.
   PubMed Web of Science ®Google Scholar
• Saunders EF, Silk KR. Personality trait dimensions and the pharmacological treatment of borderline personality disorder. J Clin Psychopharmacol. 2009 Oct;29(5):461–467.
   PubMed Web of Science ®Google Scholar
• Paolini E, Mezzetti FA, Pierri F, et al. Pharmacological treatment of borderline personality disorder: a retrospective observational study at inpatient unit in Italy. Int J Psychiatry Clin Pract. 2017 Mar;21(1):75–79. Epub 2016 Sep 27.
   PubMed Web of Science ®Google Scholar
• Starcevic V, Janca A. Pharmacotherapy of borderline personality disorder: replacing confusion with prudent pragmatism. Curr Opin Psychiatry. 2018 Jan;31(1):69–73.
   PubMed Web of Science ®Google Scholar
• Arens EA, Stopsack M, Spitzer C, et al. Borderline personality disorder in four different age groups: a cross-sectional study of community residents in germany. J Pers Disord. 2013 Apr;27(2):196–207.
   PubMed Web of Science ®Google Scholar
• Chanen AM, Kaess M. Developmental pathways to borderline personality disorder. Curr Psychiatry Rep. 2012 Feb;14(1):45–53.
   PubMed Web of Science ®Google Scholar
• World Health Organization. International classification of diseases for mortality and morbidi statistics (11th revision). Available from: https://icd.who.int/browse11/l-m/en
   Google Scholar
• Brewin CR, Cloitre M, Hyland P, et al. A review of current evidence regarding the ICD-11 proposals for diagnosing PTSD and complex PTSD. Clin Psychol Rev. 2017;58:1–15.
   PubMed Web of Science ®Google Scholar
• Haravuori H, Kiviruusu O, Suomalainen L, et al. An evaluation of ICD-11 posttraumatic stress disorder criteria in two samples of adolescents and young adults exposed to mass shootings: factor analysis and comparisons to ICD-10 and DSM-IV. BMC Psychiatry. 2016 May 12;16: 140.
   PubMed Web of Science ®Google Scholar
• Karatzias T, Murphy P, Cloitre M, et al. Psychological interventions for ICD-11 complex PTSD symptoms: systematic review and meta-analysis. Psychol Med. 2019 Aug;49(11):1761–1775.
   PubMed Web of Science ®Google Scholar